|Bid||24.04 x 1800|
|Ask||24.12 x 900|
|Day's Range||23.16 - 24.63|
|52 Week Range||19.82 - 86.30|
|Beta (5Y Monthly)||1.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||52.00|
Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced it has entered into a strategic relationship with BioLife Plasma Services, part of the global biopharmaceutical company Takeda, intended to provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies.
On Monday, Cryoport stock hit an important technical milestone, with its Relative Strength (RS) Rating rising into the 90-plus percentile with an upgrade to 91, a rise from 82 the day before. Is Cryoport Stock A Buy? On Monday, Cryoport stock retook its 200-day moving average.
With the business potentially at an important milestone, we thought we'd take a closer look at Cryoport, Inc.'s...